232 related articles for article (PubMed ID: 24479171)
1. Estradiol associated with lower thrombotic risk than conjugated equine estrogens when used as oral HRT.
Brown S
Menopause Int; 2013 Dec; 19(4):145. PubMed ID: 24479171
[No Abstract] [Full Text] [Related]
2. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
Archer DF; Oger E
Climacteric; 2012 Jun; 15(3):235-40. PubMed ID: 22612609
[TBL] [Abstract][Full Text] [Related]
3. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
[No Abstract] [Full Text] [Related]
4. Estrogen and C-reactive protein: does an alternate route lead to a more attractive destination?
Duvernoy C
Thromb Haemost; 2003 Jul; 90(1):1-2. PubMed ID: 12876618
[No Abstract] [Full Text] [Related]
5. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
[TBL] [Abstract][Full Text] [Related]
6. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
[TBL] [Abstract][Full Text] [Related]
8. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women.
Murkes D; Conner P; Leifland K; Tani E; Beliard A; Lundström E; Söderqvist G
Fertil Steril; 2011 Mar; 95(3):1188-91. PubMed ID: 21067727
[TBL] [Abstract][Full Text] [Related]
9. Safety and benefit considerations for menopausal hormone therapy.
Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
[TBL] [Abstract][Full Text] [Related]
10. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study.
Crandall CJ; Hovey KM; Andrews C; Cauley JA; Stefanick M; Shufelt C; Prentice RL; Kaunitz AM; Eaton C; Wactawski-Wende J; Manson JE
Menopause; 2017 Oct; 24(10):1145-1153. PubMed ID: 28697036
[TBL] [Abstract][Full Text] [Related]
12. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women.
Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Rosendaal FR; Psaty BM
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2807-12. PubMed ID: 16973976
[TBL] [Abstract][Full Text] [Related]
13. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
Winkler UH; Krämer R; Kwee B; Schindler AE
Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer and hormone replacement therapy.
Barton M; Meyer MR; Bolton JL; Prossnitz ER
Lancet; 2010 Jan; 375(9709):117-8; author reply 118-9. PubMed ID: 20109881
[No Abstract] [Full Text] [Related]
15. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
Shufelt CL; Merz CN; Prentice RL; Pettinger MB; Rossouw JE; Aroda VR; Kaunitz AM; Lakshminarayan K; Martin LW; Phillips LS; Manson JE
Menopause; 2014 Mar; 21(3):260-6. PubMed ID: 24045672
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology and differential cognitive efficacy of estrogen preparations.
Gleason CE; Carlsson CM; Johnson S; Atwood C; Asthana S
Ann N Y Acad Sci; 2005 Jun; 1052():93-115. PubMed ID: 16024754
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.
Modena MG; Bursi F; Fantini G; Cagnacci A; Carbonieri A; Fortuna A; Rossi R
Am J Med; 2002 Sep; 113(4):331-4. PubMed ID: 12361820
[No Abstract] [Full Text] [Related]
19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
20. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
Roach RE; Lijfering WM; Helmerhorst FM; Cannegieter SC; Rosendaal FR; van Hylckama Vlieg A
J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
